Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-06-14
2011-06-14
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S617000
Reexamination Certificate
active
07960434
ABSTRACT:
The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.
REFERENCES:
patent: 6187775 (2001-02-01), Michejda et al.
patent: 2007/0032418 (2007-02-01), Shapiro et al.
patent: WO 98/12201 (1998-03-01), None
patent: WO 00/44774 (2000-08-01), None
Song et al. Oncogene, 2003, vol. 22, pp. 4150-4165.
Chen et al. J. of Med. Chem. 1978, vol. 21, No. 9, pp. 868-874.
Becker, et al., “Three-dimensional structure of the Stat3b homodimer bound to DNA”Nature, 1998, pp. 145-151, vol. 394.
Blaskovich, et al., “Discovery of JSI-124 (Cucurbitacin I), a Selective Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathway Inhibitor with Potent Antitumor Activity against Human and Murine Cancer Cells in Mice1”Cancer Res., 2003, pp. 1270-1279, vol. 63.
Bowman, et al., “STATs in oncogenesis”Oncogene, 2000, pp. 2474-2488, vol. 19.
Bromberg, et al., “The role of STATs in transcriptional control and their impact on cellular function”Oncogene, 2000, pp. 2468-2473, vol. 19.
Bromberg, J. “Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development”Breast Cancer Res., 2000, pp. 86-90, vol. 2.
Bromberg, et al., “Stat3 as an Oncogene”Cell, 1999, pp. 295-303, vol. 98.
Buettner, et al., “Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention”Clin. Cancer Res., 2002, pp. 945-954, vol. 8.
Catlett-Falcone, et al., “Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells”Immunity, 1999, pp. 105-115, vol. 10.
Darnell, “Validating Stat3 in cancer therapy”Nat Med., 2005, pp. 595-596, vol. 11.
Darnell, “Transcription Factors As Targets for Cancer Therapy”Nat. Rev. Cancer, 2002, pp. 740-749, vol. 2.
Friesner, et al., “Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy”J. Med. Chem., 2004, pp. 1739-1749, vol. 47.
Galbaugh, et al., “EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation”BMC Cell Biol., 2006, pp. 34, vol. 7.
Garcia, et al., “Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells”Oncogene, 2001, pp. 2499-2513, vol. 20.
Gouilleux, et al., “Prolactin and Interleukin-2 Receptors in T Lymphocytes Signal through a MGF-STAT&Like Transcription Factor”Endocrinology, 1995, pp. 5700-5708, vol. 136.
Halgren, et al., “Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening”J. Med. Chem., 2004, pp. 1750-1759, vol. 47.
Jing, et al., “Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells”DNA Cell Biol., 2003, pp. 685-696, vol. 22.
Johnson, et al., “Overexpressed pp6Oc-src Can Induce Focus Formation Without Complete Transformation of NIH 3T3”Cells Mol. Cell. Biol., 1985, pp. 1073-1083, vol. 5.
Kuriyan, et al., “Modular peptide recognition domains in eukaryotic signaling”Annu Rev Biophys Biomol Struct., 1997, pp. 259-288, vol. 26.
Lee, et al., “SH2-Directed Ligands of the Lck Tyrosine Kinase”J. Med. Chem., 2000, pp. 1173-1179, vol. 43.
Mora, et al., “Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells”Cancer Res., 2002, pp. 6659-6666, vol. 62.
Nagel-Wolfrum, et al., “The Interaction of Specific Peptide Aptamers With the DNA Binding Domain and the Dimerization Domain of the Transcription Factor Stat3 Inhibits Transactivation and Induces Apoptosis in Tumor Cells”Mol Cancer Res., 2004, pp. 170-182, vol. 2.
Seidel, et al., “Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity”Proc. Natl. Acad. Sci. USA, 1995, pp. 3041-3045, vol. 92.
Shao, et al., “Structural Requirements for Signal Transducer and Activator of Transcription 3 Binding to Phosphotyrosine Ligands Containing the YXXQ Motif”J Biol Chem., 2004, pp. 18967-18973, vol. 279.
Sheinerman, et al., “Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains”J Mol Biol., 2003, pp. 823-841, vol. 334.
Shuai, K., et al., “Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions”Cell, 1994, pp. 821-828, vol. 76.
Song, et al., “A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells”Proc Natl Acad Sci USA, 2005, pp. 4700-4705, vol. 102.
Turkson, et al., “STAT proteins: novel molecular targets for cancer drug discovery”Oncogene, 2000, pp. 6613-6626, vol. 19.
Turkson, et al., “STAT proteins as novel targets for drug discovery”Expert Opin Ther Targets, 2004, pp. 409-422, vol. 8.
Turkson, et al., “Stat3 Activation by Src induces specific gene regulation and is required for cell transformation”Mol. Cell. Biol., 1998, pp. 2545-2552, vol. 18.
Turkson, et al., “Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity”Mol Cancer Ther., 2004, pp. 261-269, vol. 3.
Turkson, et al., “Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation”J. Biol. Chem., 2001, pp. 45443-45455, vol. 276.
Turkson, et al., “A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells”J Biol. Chem., 2005, pp. 32979-32988, vol. 280.
Turkson, et al., “Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity”Mol. Cancer Ther., 2004, pp. 1533-1542, vol. 3.
Wagner, et al., “The SIF binding element confers sisIPDGF inducibility onto the c-fos promoter”EMBO J., 1990, pp. 4477-4484, vol. 9.
Yu, C. L., et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.Science269, 81-83.
Yu, et al., “The stats of cancer—new molecular targets come of age”Nat. Rev. Cancer, 2004, pp. 97-105, vol. 4.
Zhang, et al., “Interdomain Interaction of Stat3 Regulates Its Src Homology 2 Domain-mediated Receptor Binding Activity”J. Biol. Chem., 2002, pp. 17556-17563, vol. 277.
Zhang, et al., “Activation of Stat3 in v-Src-transformed Fibroblast
Greedy Benjamin
Guida Wayne
Lawrence Harshani
Lawrence Nicholas J.
Sebti Said M.
H. Lee Moffitt Cancer Center & Research Institute
Jean-Louis Samira
Padmanabhan Sreeni
Saliwanchik Lloyd & Eisenschenk
University of Central Florida Research Foundation Inc.
LandOfFree
Small molecule inhibitors of STAT3 with anti-tumor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small molecule inhibitors of STAT3 with anti-tumor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small molecule inhibitors of STAT3 with anti-tumor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675864